Brief: Eloxx Pharmaceuticals Reports Positive Topline Results From Phase 2 Clinical Trial Of Elx-02 In Class 1 Cystic Fibrosis Patients
17/11/2021 12:12
Nov 17 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS REPORTS POSITIVE TOPLINE RESULTS
FROM
MONOTHERAPY ARMS OF PHASE 2 CLINICAL TRIAL OF ELX-02 IN CLASS 1
CYSTIC FIBROSIS PATIENTS
* ELOXX PHARMACEUTICALS INC - ELX-02 MONOTHERAPY RESULTS
SUPPORT
ADVANCEMENT OF ELX-02 INTO PHASE 3 CLINICAL DEVELOPMENT
* ELOXX PHARMACEUTICALS INC - TOPLINE DATA FROM PHASE 2
ELX-02
EXPECTED BY END OF FIRST HALF OF 2022
* ELOXX - ELX-02 WAS WELL TOLERATED AND ACHIEVED A
STATISTICALLY
SIGNIFICANT 5.4MMOL/L REDUCTION IN SWEAT CHLORIDE IN PATIENTS AT
THE1.5MG/KG/DAY DOSE
* ELOXX PHARMACEUTICALS INC - EXPECT TO SUBMIT AN
INVESTIGATIONAL
NEW DRUG APPLICATION IN SECOND HALF OF 2022
Source text for Eikon: ID:nGNX56T6dg
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome